OY组合在NSCLC再下一城,CTLA-4的春天来了吗?
基于CheckMate -9LA,Opdivo+Yervoy+含铂双药获批NSCLC一线,鳞癌或者非鳞癌,regardless of PD-L1 expression;
此前基于CheckMate-227 Part1a,OY组合获批NSCLC一线,PD-L1≥1%